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Abstract  
Background: Epidemiological studies of statin use in relation to prostate cancer risk have been 
inconclusive.  Recent evidence, however, suggests that longer-term use may reduce risk of 
more advanced disease.   
Methods:  We conducted a population-based study of 1,001 incident prostate cancer cases 
diagnosed in 2002-2005 and 942 age-matched controls from King County, WA, to evaluate risk 
associated with statin use.  Logistic regression was used to generate odds ratios (OR) for ever, 
current and duration of use.   
Results: There was no overall association between statin use and prostate cancer risk (OR=1.0, 
95% CI 0.8, 1.2 for current use; OR=1.1, 95% CI 0.7, 1.8 for > 10 years use), even in cases with 
more advanced disease.  Risk related to statin use, however, was modified by body mass index 
(BMI) (interaction p= 0.04).  Obese men (BMI ≥ 30 kg/m2) who used statins had an increased 
risk (OR=1.5; 95% CI 1.0, 2.2) relative to obese non-users, with a stronger association for 
longer-term use (OR=1.8, 95% CI 1.1, 3.0 for ≥ 5 years use).   
Conclusions:  Statin use was not associated with overall prostate cancer risk. Our finding of an 
increased risk associated with statin use among obese men, particularly use for extended 
durations, warrants further investigation.     
 
Key words: statins, HMG-CoA reductase inhibitors, prostate cancer, obesity, case-control study, 
odds ratio  
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INTRODUCTION 
Statin drugs are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase, the enzyme that controls the conversion of HMG-CoA to mevalonate, an 
essential precursor of cholesterol (1-3).  Statins are used to treat hypercholesterolemia and 
have been shown to reduce cardiovascular disease incidence and mortality (4-7).  Thus, use of 
statins has increased exponentially in the U.S. over the last decade (8). 
Statin use in relation to prostate cancer etiology is of interest because: 1) these drugs 
inhibit the synthesis of cholesterol, a precursor of androgens that also plays a role in cell 
signaling pathways (9); 2) mevalonate is necessary for the prenylation of proteins involved in 
signal transduction cascades downstream of membrane receptors that are crucial in cell growth 
and apoptosis (10, 11); and 3) statins inhibit cell proliferation, inflammation, oxidative stress, 
angiogenesis and metastasis in experimental models (2, 3, 11, 12).   
 Some studies suggest that statins may alter prostate cancer risk.  Randomized clinical 
trials of statin use for the prevention of cardiovascular disease reported no associations with 
prostate cancer incidence (13-15), but such trials were limited by the short durations of use and 
brief follow-up periods (16, 17).  Several observational studies showed an inverse association 
between statin use and risk of prostate cancer (18-23), although others found no association 
(24, 25, 27, 28).  The inverse association observed in some studies was limited to subgroups of 
men with advanced stage disease (20, 23), current, > 5 year users with advanced disease (21), 
or regular users of nonsteroidal anti-inflammatory drugs (NSAIDs) (22).  An increase in overall 
prostate cancer risk was observed for statin users in two studies (23, 26).  To further examine 
the potential relationship between these widely used medications and risk of prostate cancer, 
we conducted a population-based case-control study. 
 
MATERIALS AND METHODS 
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Study population   
Subjects were Caucasian and African American men residing in King County, WA, aged 
35 to 74 years.  Incident cases were diagnosed with histologically confirmed adenocarcinoma of 
the prostate from January 1, 2002 through December 31, 2005 and were identified via the 
Seattle-Puget Sound SEER cancer registry.  Caucasian cases 50-74 years were randomly 
sampled (30% of cases); 100% of eligible Caucasian cases 35-49 years and 100% of African 
American cases 35-74 years were selected.  The SEER registry provided information on 
Gleason score, tumor stage, and serum prostate-specific antigen (PSA) level at diagnosis.  Of 
the 1,327 eligible cases ascertained, 1,001 (75.4%) were interviewed.  Reasons for non-
response were: patient refusal (14.9%), physician refusal to allow patient contact (1.8%), 
inability to locate the patient (2.3%), patient moved (1.3%), patient was too ill or had other 
problems (2.6%), or death (1.7%). 
Controls without a history of prostate cancer were identified via random digit dialing, 
frequency matched to cases by five-year age groups, and recruited evenly throughout the 
ascertainment period for cases (29).  Household census information was obtained for 81.4% of 
the 24,106 residential telephone numbers contacted.  Of the 1,507 eligible controls identified, 
942 (62.5%) were interviewed.  Reasons for non-participation included: the person providing the 
household census data refused to provide information needed to send a recruitment letter to the 
eligible man in the household (10.5%), refusal (21.7%), illness (1.7%), language problem, 
moved or was lost to follow-up (3.3%), or death (0.3%).   
Subjects completed a structured in-person interview administered by a trained male 
interviewer.  The questionnaire collected demographic and lifestyle information, family history of 
cancer, medical history, medication use, and prostate cancer screening history prior to 
reference date (i.e., date of diagnosis for cases and a similar, randomly pre-assigned date for 
controls that approximated the distribution of diagnosis dates of cases).  Participants were also 
asked to complete a self-administered food-frequency questionnaire (FFQ) and to provide a 
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blood sample and consent for access to medical records. The study was approved by the 
Institutional Review Board of the Fred Hutchinson Cancer Research Center, and written 
informed consent was obtained from all study participants. 
 
Use of statin medications 
Information about statin use was obtained during the in-person interview, including ever 
use (use at least once a week for three months or longer), type of statin used (a show-card 
listing all brand names and generic names for FDA approved statin drugs was used to assist 
recall), dates of first and last use and total duration of use for each episode.  Current use was 
defined as use within the year prior to reference date.  Total duration of statin use was 
calculated as the sum of all episodes of use.  Time since first use of a statin was defined as 
years elapsed from date of first use until reference date.  In addition, statins were grouped into 
two classes:  1) lipophilic or fat soluble (lovastatin, simvastatin, atorvastatin, fluvastatin, 
cerivastatin), which may be distributed at low levels throughout the body; and, 2) hydrophilic 
(pravastatin, rosuvastatin), which act primarily in the liver.  Because all statins undergo hepatic 
first-pass metabolism, there is limited systemic bioavailability (30, 31). 
 
Genotyping 
 
 Germline DNA was used to genotype variants in two cytochrome P450 genes, CYP3A4 
(rs2740574) and CYP3A5 (rs776746).  These single nucleotide polymorphisms (SNPs) were 
selected because they affect statin metabolism (32) and thereby may influence the statin-
prostate cancer relationship.  The Applied Biosystems SNPlex™Genotyping System was used 
for genotyping (www.appliedbiosystems.com).  Quality control included genotyping 84 blind 
duplicate samples, which showed 100% agreement.  Both SNPs were in Hardy-Weinberg 
equilibrium in controls (exact p-value >0.05).   
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Statistical analyses 
 
Unconditional logistic regression was used to compute odds ratios (OR) and 95% 
confidence intervals (CI) (33).  Potential confounding was assessed by fitting models including 
each main effect and then evaluating the change in parameter estimates when other variables 
entered the models one at a time.  Covariates that changed the parameter estimates for statin 
use by > 10% were incorporated into the final model, and included age, race and prostate 
cancer screening history (none, DRE only, PSA test) within the five-year period prior to 
reference date.  Further adjustment for family history of prostate cancer, smoking status, body 
mass index (BMI), alcohol consumption, income, education, physical activity and dietary intake 
(calories, fat) did not change risk estimates associated with statin use.  Goodness of fit of 
statistical models was assessed by comparing the –2 Log Likelihood difference between nested 
models. Tests for trend were used to assess linear trends in risk estimates by duration of statin 
use. 
We also examined the association between statin use and prostate cancer by stratifying 
cases on clinical characteristics such as Gleason score (< 7, 3+4, vs. > 7, 4+3), stage (localized 
vs. regional/distant) and a composite measure of disease aggressiveness (i.e., more aggressive 
= Gleason score of > 7, 4+3 or regional/distant stage or PSA ≥ 20 ng/ml at diagnosis; less 
aggressive = Gleason score < 7, 3+4 and localized stage and PSA level < 20 ng/ml).  For these 
analyses, statin use in each group of cases was compared to that of controls using polytomous 
logistic regression.  Lastly, we examined whether associations differed by age (< 60 vs. ≥ 60 
years), race (Caucasian vs. African American), first-degree family history of prostate cancer 
(yes vs. no), BMI (< 30 vs. > 30 kg/m2), use of NSAIDs, and CYP3A4 and CYP3A5 gene 
variants.  SAS Version 9.1 was used for statistical analyses (SAS Institute, Cary, NC). 
 
RESULTS 
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Demographic and lifestyle characteristics of cases and controls are presented in Table 
1. Cases were more likely than controls to report a first-degree family history of prostate cancer 
(23% vs. 12%) and to have had PSA screening in the five years before reference date (71% vs. 
58%).  Cases and controls were similar with respect to BMI, smoking status, alcohol 
consumption, education, and recent exercise frequency.  The prevalence of 
hypercholesterolemia for which statins are primarily prescribed was similar between cases and 
controls, 43% vs. 40%, respectively (age-adjusted OR=1.07; 95% CI 0.89, 1.29).  With respect 
to clinical characteristics of prostate cancer, 31% of the cases were classified as having “more 
aggressive” disease.   
The prevalence of any statin use among controls was 28%.  Table 2 shows comparisons 
between users and non-users in the control group.  Statin users were older, more likely to be 
Caucasian, have a higher BMI, be former smokers, and have undergone PSA screening.  There 
were no differences, however, with respect to first-degree family history of prostate cancer.  
Users of statin medications had a higher prevalence of self-reported hypercholesterolemia, 
diabetes mellitus, hypertension, myocardial infarction or stroke in comparison to non-users (all 
p-values <0.0001).    
 The prevalence of statin use was similar in prostate cancer cases and controls (OR = 
0.98, 95% CI 0.80, 1.21) (Table 3).  No associations were observed with other measures of 
statin use (current use, duration of use, age at first use, time since first use).  In relation to the 
type of statin used, most cases and controls reported using atorvastatin (18.3% and 17.8%, 
respectively), followed by simvastatin (9.1% and 9.2%, respectively), pravastatin and lovastatin 
(4.2% and 4.0% respectively for each drug).  The prevalence of use of other types of statins 
was low (< 2%).  Statins were also grouped as hydrophilic or lipophilic, but no association was 
found for either group. 
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 Next, we examined statin use and prostate cancer risk according to clinical features 
(Table 4).  There were no associations between statin use and Gleason score (<7, 3+4 vs. >7, 
4+3), tumor stage (local vs. regional/distant) or prostate cancer aggressiveness status (less vs. 
more).  In a subset analysis of metastatic or fatal prostate cancer (n= 27 cases), we found an 
OR of 0.24 (95% CI 0.05, 1.02) for ever use; however, only two cases who used a statin < 12 
months contributed to this observation.   
Lastly, we examined statin use in relation to prostate cancer in analyses stratified by age 
(< 60 vs. ≥ 60 years), race (Caucasian vs. African American), first-degree family history of 
prostate cancer (yes vs. no), BMI (< 30 vs. ≥ 30 kg/m2), use of NSAIDs, and CYP3A4 and 
CYP3A5 gene variants.  No differences in risk estimates were observed for any of these other 
factors, except for BMI (Table 5).  A statistically significant statin use by BMI interaction was 
observed for ever use (interaction p= 0.03) and for duration of use (interaction p= 0.04).  No 
association was observed among non-obese men, but in obese men (BMI ≥ 30 kg/m2) statin use 
increased risk (OR = 1.5) relative to no use.  The relative risk was higher in obese, long-term 
users (OR = 1.8; 95% CI 1.1, 3.0 for ≥ 5 years of use).   
 
Discussion 
In this study there were no associations between detailed measures of statin use and 
either risk of prostate cancer overall or of more aggressive disease.  Interestingly, analyses 
stratified by BMI showed that obese men (BMI ≥ 30 kg/m2) who reported current use of a statin 
had an increased relative risk of prostate cancer (OR = 1.5, 95% CI 1.0, 2.1), which was 
stronger in those with extended durations of use (OR = 1.8 for > 5 years of use).  
Several randomized clinical trials of cardiovascular disease (13-15) as well as 
observational studies (19-28) have examined risk of prostate cancer in relation to statin use.  
The randomized trials data revealed no associations (13-15), but the trials were not designed to 
test the statin-prostate cancer hypothesis.  Moreover, these trials involved short durations of 
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statin use and limited periods of follow-up, which are likely inadequate for assessing statin use 
in relation to cancer occurrence (16).     
Several observational studies have examined the association between statin use and 
prostate cancer (19-28).  Most of these studies utilized hospital- or clinic-based populations or 
computerized pharmacy data for analyses.  The prevalence of statin use varied widely across 
studies, ranging from 5% to 49%, and in some studies increased over time.  Two studies 
reported an overall inverse association between any statin use and prostate cancer risk (18, 
19), while others reported no association (24, 25, 27, 28) or a positive association (23, 26).  
Shannon and colleagues (19) conducted a study within a Veterans Administration hospital 
population and reported an OR of 0.4 (95% CI 0.2, 0.7) for prostate cancer in relation to ever 
use of a statin and an OR of 0.3 for > 2 years duration of use.  Graaf et al. (18) used a 
pharmacy database to define exposure and observed a similar reduction in risk (OR = 0.4) of 
prostate cancer in relation to statin prescriptions.  However, both of these studies had small 
sample sizes.  Recently, Flick and colleagues (22) used data from the California Men’s Health 
Study cohort to evaluate statin exposure and also reported an inverse association between ≥ 5 
years of statin use and overall prostate cancer risk (RR = 0.72; 95% CI 0.53, 0.99). The 
remaining studies reported no associations with overall prostate cancer risk, with the exception 
of two studies.  Data from the United Kingdom GPRD database (26) revealed a modest 
increase in prostate cancer risk (OR = 1.3; 95% CI 1.0, 1.9) associated with use of a statin drug, 
and a large population-based study from Finland (23) also reported an elevated risk estimate in 
statin users (OR = 1.07; 95% CI 1.0, 1.2).    
 With respect to clinical features of prostate cancer, Shannon and colleagues (19) 
reported an OR of 0.3 (95% CI 0.1, 0.5) in men with a Gleason score of > 7 in relation to ever 
use of a statin.  In another recent analysis based on the Health Professionals Follow-up Study, 
Platz et al. (20) reported a significant reduction in risk of advanced stage disease (RR = 0.5; 
95% CI 0.3, 0.9) and metastatic or fatal prostate cancer (RR = 0.4; 95% CI 0.2, 0.8) among 
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users of cholesterol-lowering medications.  An inverse association between statin use and 
advanced prostate cancer was also noted in some other studies (21-23).  In the Cancer 
Prevention Study II Nutrition Cohort, long-term (≥ 5 years) statin use was associated with a 
reduction in risk of advanced prostate cancer (stage III, IV or fatal; RR = 0.60; 95% CI 0.36, 
1.00) (21).  Similar findings were observed in the California Men’s Health Study Cohort for risk 
of regional/distant stage disease in relation to statin use lasting for ≥ 5 years (RR = 0.57; 95% 
CI 0.2, 1.4), although this result was not statistically significant.  In a third study that included 
24,723 prostate cancer cases identified via the Finnish Cancer Registry, Murtola and colleagues 
(23) also reported an inverse association between statin use that was limited to advanced stage 
disease (OR = 0.75; 95% CI 0.62, 0.91), with a dose-response relationship (p trend=0.001).                     
 In our study we evaluated several measures of statin use (ever, current, duration of use) 
in relation to clinical features of prostate cancer such as Gleason score, tumor stage and a 
composite measure of more aggressive disease, but found no associations.  In the subset of 
cases with regional or distant stage, there was a non-significant reduction in risk in current statin 
users relative to non-users (OR = 0.73; 95% CI 0.5, 1.1).  We also analyzed data according to 
distant stage or fatal prostate cancer and found an inverse association between ever use of a 
statin medication (OR = 0.24; 95% CI 0.05, 1.02) and metastatic or fatal disease, but there were 
only two exposed cases in this analysis and both had used a statin for less than one year.  
These findings, however, are consistent with the hypothesized anti-metastatic activitiy of statins 
(3, 11).   
In relation to BMI, the Cancer Prevention Study II Nutrition Cohort investigators reported 
an interaction between long-term use of cholesterol-lowering drugs and BMI (p=0.02) for 
advanced prostate cancer, but not for overall prostate cancer (21).  However, in that study there 
were no obese cases with advanced disease among long-term users of cholesterol-lowering 
drugs.  In our study, there were 74 obese cases with more aggressive disease features, and of 
these, 13 (18%) had used a statin for ≥ 5 years.  The prevalence of long-term (> 5 years) statin 
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use in the obese, more aggressive disease subgroup was not markedly different in comparison 
to the prevalence of long-term use (22%, p=0.3) in obese men with less aggressive disease.  
There is no clear biological mechanism to explain why statin use may preferentially increase risk 
of prostate cancer in obese men.  Data from our control group show that statin users have 
higher BMIs and are more likely to have co-morbid conditions that may be indications for statin 
use. These medical conditions may also be associated with altered hormone levels that could 
affect prostate cancer risk.  Of interest in this regard is a recently published study that found no 
difference in circulating levels of androgens between statin users compared to non-users (34), 
but levels of sex hormone-binding globulin (SHBG) were significantly lower in statin users.  With 
respect to the latter finding, a recent meta-analysis of studies of endogenous sex hormones and 
prostate cancer revealed that men with lower levels of SHBG are at higher risk for developing 
prostate cancer (35).  Another potential mechanism described by Goldstein et al. (36) is the 
ability of statin medications to increase the level of regulatory T cells, which may suppress anti-
tumor T cell response and thereby enhance cancer risk.       
Our study has several strengths and limitations that should be considered when 
interpreting these results.  Strengths are its population-based approach, sample size and the 
fact that it was designed to test the association between statin use and risk of prostate cancer.   
In addition, we had detailed information about statin use that allowed us to evaluate duration of 
use, time since first use, time since last use, age at first use and type of statin used.  One 
concern in observational studies is the accuracy of self-reported exposures.  In an attempt to 
address this issue, we compared self-reported use of statins (162 cases, 162 controls) with data 
from a computerized pharmacy database maintained by Group Health Cooperative of Puget 
Sound.  There was 87% agreement for any use of a statin (90% and 85% agreement for cases 
and controls, respectively).   
Another issue is that of potential confounding by prostate cancer screening, which is 
correlated with statin use and prostate cancer diagnosis.  We evaluated the statin-prostate 
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cancer relationship after adjusting for various measures of prostate cancer screening: 1) any 
tests (none, DRE only, PSA) done within the five-year period before reference date; 2) the 
number of PSA tests (0, 1-2, 3-4, 5+) done within the five-year period before reference date; 
and 3) the time interval since the most recent PSA test and reference date.  Prostate cancer 
screening questions were asked in such a way so as to excluded diagnostic tests, and only 25 
cases and 38 controls reported having a PSA screening test within four months of reference 
date.  We also analyzed our data excluding men (84 cases, 46 controls) who reported that they 
“had a problem or symptom” at the time of the most recent PSA test prior to reference date, and 
performed separate analyses in men who reported having a PSA screening test within the five 
years before reference date and in men who reported no such screening.  Results from these 
analyses were similar to the risk estimates presented, which are adjusted for any prostate 
cancer screening tests within the five years prior to reference date.   
Other concerns include potential selection bias and recall bias. There is a possibility that 
men who did not participate had a different prevalence of statin use than those who joined the 
study.   Although we have no data on non-participants, it is reassuring that the prevalence of 
statin use in our control group (28%) is similar to the prevalence estimates of 25% (21) and 27% 
(22) for statin use reported from other recently studies. Standardized interviews, medication 
show cards and trained interviewers were used to enhance reporting of drug use.  Lastly, the 
prevalence of long-term statin use (> 10 years) is low (4% in controls) since these medications 
only became available in the U.S. in 1987.  Thus, our study as well as other studies reported to 
date was underpowered to address the relationship between extended periods of statin use (> 
10 years) and risk of developing prostate cancer. 
In conclusion, results of this study suggest that statin use is not associated with overall 
prostate cancer risk.  However, obese men who use statin medications, particularly for longer 
durations, have an increased risk of prostate cancer relative to obese non-users.  This latter 
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observation warrants further investigation, particularly given the high prevalence of both statin 
use and of obesity in the general population.   
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Table 1. Selected demographic, lifestyle and clinical characteristics of population-based 
prostate cancer cases and controls, King County, WA, 2002-2005 
 
Characteristic Cases 
(n=1,001) 
Controls 
(n=942) 
OR* 95% CI 
Age (years)   n † %   n † %     
     < 50   93 9.3   96 10.2     
     50 - 54 108 10.8 113 12.0     
     55 - 59 184 18.4 174 18.5     
     60 - 64 218 21.8 187 19.9     
     65 - 69 210 21.0 202 21.4     
     70 - 74 188 18.8 170 18.0     
Race             
    Caucasian 843 84.2 844 89.6 1.00  
    African American 158 15.8 98 10.4 1.68 1.28, 2.21 
First-degree family history of 
prostate cancer 
            
    No 775 77.4 833 88.4 1.00  
    Yes 226 22.6 109 11.6 2.24 1.75, 2.87 
Body mass index (BMI, kg/m2)             
    < 25  287 28.7 259 27.5 1.00  
    25.0 - 29.9 492 49.2 444 47.1 1.00 0.81, 1.24 
    ≥ 30 222 22.2 239 25.4 0.84 0.66, 1.08 
Smoking status             
    Non-smoker 428 42.8 429 45.6 1.00  
    Former smoker 462 46.2 394 41.9 0.95 0.71, 1.27 
    Current smoker 111 11.1 118 12.5 1.16 0.96, 1.40 
Lifetime alcohol consumption 
(drinks/week) 
                  
    Non-drinker or <1 drink 222 22.2 234 24.8 1.00  
    Low (1-7) 354 35.4 316 33.5 1.18 0.93, 1.50 
    Moderate (8-14) 222 22.2 205 21.8 1.15 0.88, 1.49 
    High (≥ 15) 203 20.3 187 19.9 1.16 0.88, 1.52 
Recent exercise (times/week)             
    None 262 26.2 246 26.1 1.00  
    1 - 2 315 31.5 283 30.0 1.06 0.84, 1.35 
    3 - 4 251 25.1 244 25.9 0.98 0.76, 1.26 
    ≥ 5  172 17.2 168 17.9 0.96 0.73, 1.26 
Education             
     High school or less 196 19.6 181 19.2 1.00  
     Some college  241 24.1 210 22.3 1.08 0.82, 1.42 
     College degree 262 26.2 261 27.7 0.95 0.72, 1.24 
     Graduate degree 301 30.1 289 30.7 0.98 0.75, 1.27 
Prostate cancer screening ‡              
     None 133 13.3 136 14.4 1.00  
     DRE only 159 15.9 263 27.9 0.62 0.45, 0.84 
     PSA  709 70.8 543 57.6 1.34 1.02, 1.75 
NSAIDs use             
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     None 792 79.1 746 79.1 1.00  
     Former use   78   7.8   70   7.4 1.07 0.76, 1.51 
     Current use 131 13.1 126 13.4 0.98 0.75, 1.28 
CYP3A4 (rs2740574) genotype       
     AA 665 82.4 663 85.3   1.00 §  
     AG 100 12.4   94 12.1 0.83 0.58, 1.19 
     GG   42   5.2   20   2.6 1.19 0.59, 2.43 
CYP3A5 (rs776746) genotype       
     GG 624 76.2 623 79.5   1.00 §  
     GA 143 17.5 134 17.1 0.95 0.71, 1.26 
     AA   52   6.3   27   3.4 1.17 0.62, 2.21  
Hypercholesterolemia       
    No 572 57.1 556 59.0 1.00  
    Yes 425 42.5 380 40.3 1.07 0.89, 1.29 
Gleason score          
     2 - 6 525 52.4     
     7 (3+4) 294 29.4     
     7 (4+3)   78   7.8     
     8 - 10   99   9.9     
     Unknown     5   0.5     
Stage of cancer         
    Local 818 81.7     
    Regional 159 15.9     
    Distant   22   2.2     
    Unknown    2   0.2     
 PSA value (ng/ml) at diagnosis         
      < 4.0 134 13.4     
      4.0 - 9.9 592 59.1     
     10.0 - 19.9  143 14.3     
     ≥ 20.0    69   6.9     
     Unknown   63   6.3     
Prostate cancer aggressiveness ¶         
   Less aggressive 686 68.5     
   More aggressive 315 31.5     
* Odds ratios (OR) are adjusted for age. 
† Numbers may not add total due to missing data. 
‡ Prostate cancer screening within the 5 year period before reference date. 
§ Odds ratios are adjusted for age and race. 
¶ More aggressive = Gleason score of 7(4+3) or 8-10 or regional or distant stage or a diagnostic    
PSA ≥ 20 ng/ml; Less aggressive = Gleason score of 2-6 or 7(3+4) and localized stage and a 
diagnostic PSA < 20 ng/ml. 
 16
Table 2.  Distribution of selected demographic and lifestyle characteristics and medical 
conditions between users and non-users of statins among population-based controls, 
King County, WA, 2002-2005 
 
Characteristic Statin Users 
(n = 265) 
Statin Non-Users 
(n = 677) 
P-
value*  
Age (years)   n † % n † % <0.0001
     < 50 11   4.2   85 12.6   
     50 - 54 15   5.7   98 14.5   
     55 - 59 41 15.5 133 19.6   
     60 - 64 65 24.5 122 18.0   
     65 - 69 65 24.5 137 20.2   
     70 - 74 68 25.7 102 15.1   
Race         0.04 
    Caucasian 246 92.8 598 88.3   
    African-American   19   7.2   79 11.7   
First-degree family history of prostate 
cancer 
        0.45 
    No 231 87.2 602 88.9   
    Yes   34 12.8   75 11.1   
BMI (kg/m2)         0.01 
    < 25.0   55 20.8 204 30.1   
   25.0 - 29.9 134 50.6 310 45.8   
   ≥ 30.0   76 28.7 163 24.1   
Smoking status          0.01 
    Non-smoker 104 39.2 325 48.0   
    Former smoker 132 49.8 262 38.8   
    Current smoker 29 10.9 89 13.2   
Lifetime alcohol consumption 
(drinks/week) 
        0.33 
    Non-drinker or <1 74 27.9 160 23.6   
    Low (1-7) 87 32.8 229 33.8   
    Moderate (8-14) 49 18.5 156 23.0   
    High (≥ 15) 55 20.8 132 19.5   
Recent exercise (times/week)         0.63 
    None 71 26.8 175 25.9   
    1 - 2 77 29.1 206 30.5   
    3 - 4 63 23.8 181 26.8   
    ≥ 5  54 20.4 114 16.8   
Education          0.15 
     High school or less 47 17.7 134 19.8   
     Some college or vocational 73 27.5 137 20.2   
     Bachelors college degree 65 24.5 196 29.0   
     Graduate school  80 30.2 209 30.9   
Prostate cancer screening ‡         <0.0001
     None 19 7.2 117 17.3   
     DRE only 59 22.3 204 30.1   
     PSA  187 70.6 356 52.6   
Hypercholesterolemia         <0.0001
    No   19   7.2 537 79.9   
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    Yes 245 92.8 135 20.1   
Diabetes mellitus         <0.0001
    No 209 78.9 632 93.4   
    Yes   56 21.1   45   6.6   
Hypertension         <0.0001
    No 109 41.1 491 72.5   
    Yes 156 58.9 186 27.5   
Myocardial infarction         <0.0001
    No 202 76.2 660 97.5   
    Yes   63 23.8   17   2.5   
Stroke         <0.0001
    No 249 94.0 658 97.6   
    Yes   16   6.0   16   2.4   
* Chi-square p-value.  
† Numbers may not add to total due to missing data. 
‡ Prostate cancer screening within the 5 year period before reference date. 
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Table 3.  Associations between statin use and prostate cancer risk in a population-based   
case-control study, King County, WA, 2002-2005   
 
 Cases 
(n = 1,001) 
Controls 
(n = 942) OR* 95% CI 
Statin use n % n %   
  None 712 71.1 677 71.9 1.00  
  Ever use 289 28.9 265 28.1 0.98 0.80, 1.21 
  Current use 272 27.2 244 25.9 1.00 0.81, 1.24 
  Duration of use, yrs.       
       < 5.0 154 15.4 146 15.5 0.96 0.74, 1.23 
       5.0 - 9.9   90   9.0   81   8.6 0.97 0.70, 1.34 
       ≥ 10    45   4.5   38   4.0 1.11 0.70, 1.75 
       Continuous    1.01 0.98, 1.03 
  Age at first use       
      < 59 † 166 16.6 138 14.6 1.11 0.86, 1.43 
      ≥ 59 123 12.3 127 13.5 0.81 0.60, 1.07 
 Time since first use, yrs.       
      < 5 145 14.5 133 14.1 0.96 0.74, 1.24 
      ≥ 5 144 14.4 132 14.0 0.97 0.75, 1.27 
  Type of statin used ‡       
       Hydrophilic   42   4.2   42   4.5 0.91 0.58, 1.44 
       Lipophilic 274 27.4 246 26.1 1.02 0.83, 1.27 
 
* ORs are adjusted for age, race, and prostate cancer screening within the 5 year period      
before reference date. 
    † Age 59 was the median age at first use of a statin medication among controls. 
    ‡ Hydrophilic statins = pravastatin, rosuvastatin; lipophilic statins = lovastatin, simvastatin, 
    atorvastatin, fluvastatin, cerivastatin; some cases (n=27) and controls (n=24) reported use of 
  both types, so the analysis was also adjusted for the other type used.  
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Table 4.  Associations between statin use and clinical characteristics of prostate cancer in a population-based  
case-control study, King County, WA, 2002-2005   
 
a. Gleason score 
 Controls 
(n = 942) 
Cases, Gleason score < 7 (3+4) 
(n = 816) 
Cases, Gleason score > 7 (4+3) 
(n = 177) 
Statin use n % n % OR* 95% CI n % OR* 95% CI 
 None 677 71.9 584 71.6 1.00  120 67.8 1.00  
 Ever use 265 28.1 232 28.4 0.96 0.77, 1.19   57 32.2 1.14 0.80, 1.63 
 Current use 244 25.9 220 27.0 0.99 0.79, 1.23   52 29.4 1.12 0.78, 1.62 
 Duration, yrs.       
      < 5 146 15.5 127 15.6 0.96 0.73, 1.26   27 15.3 1.00 0.63, 1.58 
      ≥ 5 119 12.6 105 12.9 0.97 0.72, 1.29   30 16.9 1.31 0.83, 2.07 
     Continuous           0.99 0.97, 1.03   1.02 0.98, 1.07 
 
b. Tumor stage  
 Controls 
(n = 942) 
Cases, localized stage 
(n = 818) 
Cases, regional/distant stage 
  (n =181) 
Statin use n % n % OR* 95% CI n % OR* 95% CI 
 None 677 71.9 568 69.4 1.00     142 78.5 1.00     
 Ever use 265 28.1 250 30.6 1.03 0.83, 1.27   39 21.5 0.79 0.53, 1.17 
 Current use 244 25.9 239 29.2 1.07 0.86, 1.33   33 18.2 0.73 0.48, 1.10 
 Duration, yrs.       
      < 5 146 15.5 136 16.6 1.03 0.79, 1.34   18   9.9 0.65 0.38, 1.11 
      ≥ 5 119 12.6 114 13.9 1.03 0.77, 1.37   21 11.6 0.96 0.58, 1.60 
     Continuous           1.00 0.97, 1.03   0.99 0.94, 1.04 
 
c. Disease aggressiveness † 
 Controls 
(n = 942) 
Cases, less aggressive 
(n = 686) 
Cases, more aggressive 
(n = 315) 
Statin use n % n % OR* 95% CI n % OR* 95% CI 
 None 677 71.9 478 69.7 1.00  234 74.2 1.00  
 Ever use 265 28.1 208 30.3 1.01 0.81, 1.27   81 25.8 0.92 0.68, 1.23 
 Current use 244 25.9 199 29.0 1.05 0.83, 1.32   73 23.2 0.89 0.66, 1.22 
 20
 Duration, yrs.       
      < 5 146 15.5 116 16.9 1.04 0.78, 1.37 38 12.1 0.78 0.53, 1.15 
      ≥ 5 119 12.6 92 13.4 0.98 0.73, 1.34 43 13.7 1.08 0.73, 1.59 
      Continuous           1.00 0.97, 1.04   1.00 0.96, 1.04 
* ORs are adjusted for age, race, and prostate cancer screening within the 5 year period before reference date; 
 respective analyses exclude cases with missing Gleason score (n=8) or stage (n=2). 
† More aggressive = Gleason score of 7(4+3) or 8-10 or regional or distant stage or a diagnostic PSA ≥ 20 ng/ml; 
 Less aggressive = Gleason score of 2-6 or 7(3+4) and localized stage and a diagnostic PSA < 20 ng/ml. 
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Table 5.  Associations between statin use and prostate cancer risk stratified by body mass index 
(BMI), in a population-based case-control study, King County, WA, 2002-2005   
 
BMI < 30 kg/m2 Cases          
(n = 779) 
Controls 
(n = 703) OR* 95% CI 
Statin use n % n %   
 None 582 74.7 514 73.1 1.00  
 Ever use 197 25.3 189 26.9 0.87 0.68, 1.11 
 Current use 187 24.0 176 25.0 0.89 0.69, 1.14 
 Duration of use, yrs.       
      < 5 108 13.9 101 14.4 0.91 0.67, 1.23 
      ≥ 5   89 11.4   88 12.5 0.83 0.59, 1.15 
      Continuous            0.99 0.96, 1.02 
       
BMI ≥ 30 kg/m2 Cases          
(n = 222) 
Controls       
(n = 239) 
 
OR* 
 
95% CI 
Statin use n % n %   
  None 130 58.6 163 68.2 1.00  
  Ever use   92 41.4   76 31.8 1.45 0.99, 2.13 
  Current use   85 38.3   68 28.5 1.50 1.00, 2.24 
 Duration of use, yrs.       
      < 5   46 20.7   45 18.8 1.21 0.75, 1.96 
      ≥ 5   46 20.7   31 13.0 1.80 1.06, 3.03 
      Continuous            1.05 1.00, 1.10 
* ORs are adjusted for age, race, and prostate cancer screening within the 5 year period before 
reference date. 
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